- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02629055
Respiratory EMG for NIV Titration in Stable COPD Patients
EMG Measurements of Respiratory Muscles for the Titration of Nocturnal Non-invasive Ventilation in Stable Chronic Obstructive Pulmonary Disease Patients: A Randomized Controlled Trial
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Rationale:
Long-term application of nocturnal non-invasive ventilation (NIV) in stable hypercapnic chronic obstructive pulmonary disease (COPD) patients has long been controversial as study results were not unequivocal. However, in the past 7 years, with a change in ventilatory strategy, clear benefits of chronic NIV have been shown in COPD patients with chronic hypercapnic respiratory failure (CHRF), though only in stable disease. As a consequence, this so called high-intensity NIV, which is the concept of using higher positive inspiratory airway pressures (IPAP) levels than used in most of the older trials in addition to controlled ventilation with higher backup breathing frequencies aiming for maximal arterial carbon dioxide (PaCO2) reduction, has gained increasing attention.
However, it is unknown how high-intensity NIV works, and how to titrate the optimal IPAP and optimal backup breathing frequency. Measuring respiratory muscle activity might be a way to titrate NIV in COPD.
Objective:
The aim of the present study is to investigate whether additional titration on surface electromyography (EMG) of the diaphragm and intercostal muscles improves outcomes of chronic NIV in patients with COPD and stable CHRF in terms of better gas exchange after six weeks, lung function, patient comfort and compliance and less patient-ventilator asynchrony (PVA).
Study design:
A randomized, two-armed, crossover trial comparing regular titration with additional respiratory EMG titration of NIV in stable hypercapnic COPD.
One group will be initiated on NIV according to standard care protocol. For the other group, additional EMG measures whilst on NIV will be made to titrate NIV.
Protocol Regular NIV-set up (both groups) Subjects are initiated on NIV according to our own local treatment protocol. NIV is initiated by a registered nurse of our home mechanical ventilation (HMV) centre. Effectiveness is measured with transcutaneous measurements of carbon dioxide (PtCO2).
NIV is supplied through a pressure cycled ventilator, applying both inspiratory airway pressure and expiratory airway pressure to the patient (BiPAP; Synchrony, Respironics, incorporated., Murrysville, USA). A nasal or full face mask (Mirage mask, ResMed Ltd, UK) of proper size is used. The ventilator is set in a spontaneous/ time mode (S/T), with a backup frequency. If needed O2 was added to obtain a saturation of ≥ 90%. A humidifier (HC 150 Fisher & Paykel Healthcare, Australia) is used if needed. In general, the nurse aims to reach a setting with high inspiratory pressures and a moderate breathing backup frequency, with good patient comfort.
Start of the study Patients will be included in the study once they is used to the mask, can sleep at least 6 hours with the ventilator and settings are set as is usual in daily clinical practice. This means that the initial NIV settings are optimized according to the results of an overnight PtCO2 and patient comfort. In daily practice, the specialized nurses of the HMV centre already aim to increase the inspiratory pressure to the highest pressure that is still comfortable for the patient, so that all patients will already be at their highest tolerable pressure.
Once patients agree to participate, a 15-minute EMG measurement is done in all patients while they are ventilated with the settings at that particular moment. Furthermore, patients are asked to complete the severe respiratory insufficiency (SRI) questionnaire.
In the "nurse titrated NIV" group, no additional changes are made to the ventilatory settings. In the "EMG titrated NIV" group, after a 15-minute EMG with the ventilatory settings set by the nurse, the nurse will decrease the backup breathing frequency set by the ventilator by steps of 2 breaths/min to 8 breaths/min (to achieve a pressure support mode of ventilation (completely triggered by the patient)) and then again up to a frequency 2 breaths/min above their spontaneous breathing frequency while on the ventilator (to achieve a controlled mode of ventilation). Each frequency will be measured for 10 minutes, so that the total titration will take about 60-80 minutes. EMG measurements will be done throughout the whole session and will be analyzed the same day. Then, the setting is chosen with the lowest EMG activity and least PVA. The next night an EMG measurement is performed at the chosen setting.
6 weeks After 6 weeks, the overnight EMG measurement is repeated in all patients. Furthermore, a nocturnal PtCO2 measurement is performed, patients are asked to rate how comfortable the patient is with the settings and are asked to fill in the SRI, lung function is assessed and the number of hours use per night is read from the ventilator counting reading. After these measurements are performed, patients are directed to the other titration arm. In patients initially titrated by the nurse, an EMG frequency titration is performed as described above. In the patients initially titrated additionally on the EMG, the investigators will reset the ventilator to the settings applied by the nurse initially.
12 weeks After 12 weeks, the nocturnal EMG measurement, the nocturnal transcutaneous CO2 measurement, the comfort score, the SRI, lung function assessment and compliance rating are repeated in all patients.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
-
Groningen, Netherlands, 9700RB
- University Medical Center Groningen
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Chronic Obstructive Pulmonary Disease (COPD) Global initiative of chronic Obstructive Lung Diseases (GOLD) stage III or IV (FEV1 <50 % predicted, FEV1/forced expiratory volume (FVC) < 70% predicted)
- Indication for the initiation of chronic NIV: PaCO2 >6.0 kilopascal (kPa) at rest during daytime.
- Stable COPD (pH >7.35, no exacerbation in the past two weeks)
- Age >18 years
Exclusion Criteria:
- Respiratory insufficiency of any other cause.
- Already initiated on chronic NIV.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Respiratory EMG
Additional EMG measurements whilst on NIV will be used to guide the titration of NIV.
|
Titration of non-invasive ventilation on surface respiratory muscle activity
|
No Intervention: Care as usual
NIV will be initiated according to standard care protocol.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Nocturnal gas exchange (PCO2 (kPa))
Time Frame: 6 weeks
|
PCO2 will be assessed with transcutaneous measurements (TOSCA, Linde Medical Sensors AG, Basel)
|
6 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Patient comfort measured with a Visual Analogue Scale
Time Frame: 6 weeks
|
comfort with NIV setting, measured with a Visual Analogue Scale
|
6 weeks
|
Health related quality of life measured with the Severe Respiratory Insufficiency (SRI) questionaire
Time Frame: 6 weeks
|
Measured with the Severe Respiratory Insufficiency (SRI) questionaire
|
6 weeks
|
Lung volumes
Time Frame: 6 weeks
|
Total Lung Capacity (liters) and Residual Volume (liters))
|
6 weeks
|
Respiratory muscle strength
Time Frame: 6 weeks
|
Maximal inspiratory pressure (kPa)).
|
6 weeks
|
Patient-Ventilator Asynchrony (PVA)
Time Frame: 6 weeks
|
The investigators will assess PVA's by simultaneously comparing EMG recordings with pressure waves delivered by the ventilator.
PVA's are measured as a percentage of the total number of delivered breaths
|
6 weeks
|
Collaborators and Investigators
Investigators
- Principal Investigator: Marieke L Duiverman, Dr, UMCG
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 2015/383
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Chronic Obstructive Pulmonary Disease (COPD)
-
University College, LondonUniversity of Cambridge; National Institute for Health Research, United Kingdom and other collaboratorsUnknownChronic Obstructive Pulmonary Disease (COPD).United Kingdom
-
Reham Mohammed ElmorshedyCompletedChronic Obstructive Pulmonary Disease(COPD)Egypt
-
AstraZenecaCompletedChronic Obstructive Pulmonary Disease (COPD).United Kingdom
-
Virginia Commonwealth UniversityFisher and Paykel HealthcareCompletedChronic Obstructive Pulmonary Disease(COPD)United States
-
Beaumont HospitalAerogenCompletedChronic Obstructive Pulmonary Disease | COPD | COPD Exacerbation | Copd Exacerbation AcuteIreland
-
Medtronic BRCUnknownCOPD | COPD Exacerbation
-
Chiesi Farmaceutici S.p.A.CompletedModerate to Severe Chronic Obstructive Pulmonary Disease (COPD)Bulgaria, Germany, Hungary, Poland, Russian Federation, United Kingdom
-
Chiesi Farmaceutici S.p.A.CompletedChronic Obstructive Pulmonary Disease (COPD) | COPDUnited Kingdom
-
Elpen Pharmaceutical Co. Inc.Completed
-
Aalborg UniversityCompletedChronic Obstructive Pulmonary Disease | COPD | COPD Exacerbation | COPD Exacerbation AcuteDenmark
Clinical Trials on Respiratory EMG
-
Riyadh Colleges of Dentistry and PharmacyUnknown
-
dr. schwandnerUnknown
-
University of GiessenCompleted
-
Newcastle UniversityNewcastle-upon-Tyne Hospitals NHS TrustNot yet recruitingElectromyography
-
Kocaeli UniversityCompletedStroke | Dysphagia | Surface Electromyography | Swallowing Disorder | BiofeedbackTurkey
-
Yuzuncu Yıl UniversityCompleted
-
Cairo UniversityCompletedHeavy Smart Phone UsersEgypt
-
October 6 UniversityActive, not recruiting
-
Yuzuncu Yıl UniversityCompleted
-
Assiut UniversityRecruiting